An observational study in Pulmonary Embolism (PE), Right-to-Left Shunt and Stroke, sponsored by Tufts Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Tufts Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Pulmonary Embolism with a site in United States — 34 open to participants now, 43 under way, 6 of them phase 3. Pulmonary Embolism · United States.
Among the 236 studies in Pulmonary Embolism with a site in United States, this one is the 37th largest by planned enrollment of the 68 observational ones that give a count, is one of 13 that started in 2026, is one of 69 observational ones, reaches primary completion later than 6 of the 42 other live ones, and was the 232nd registered.
833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.
Browse Pulmonary Embolism studies →34 of the 236 studies in Pulmonary Embolism with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Bulgaria, Japan and 2 more countries
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 21+
Brigham and Women's Hospital · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Canada
Ages 18+
Angiodynamics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 17 · Phase 3 38 · Phase 4 21
First in 1999; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 256 is below the median of 361 across 366 observational studies indexed under Pulmonary Embolism.
Median enrollment 142 across the 166 interventional studies, 286 across the 68 observational. Of the 169 that completed or were terminated, 76 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
78 of 236 have an industry lead sponsor. The 10 most frequent:
Tufts Medical Center is the lead sponsor of 200 studies on the registry; 27 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 16 (48%) have results posted.
Tufts Medical Center has 1 study filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
17 of the studies in Pulmonary Embolism with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05591118Phase 3NYU Langone HealthPulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy | 2027-03-29 |
| NCT07213778Phase 3Regeneron PharmaceuticalsREGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | 2027-05-17 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
| NCT04798261Penumbra Inc.Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 236 studies in Pulmonary Embolism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Every fetus has a small hole in their heart, called a foramen ovale when they are developing in the womb. For most people this hole closes shortly after birth, but it doesn't close completely in 1 out of every 4 people. This is called a "patent" foramen ovale, or PFO. In people with a PFO it is possible for a blood clot in a vein to enter the heart, pass through the opening, and then go into an artery - this is referred to as a paradoxical embolism which passes through a "Right-to-Left Shunt," or RLS. If this occurs, the blood clot can cause a stroke. The most common RLS (more than 90%) is a PFO. Much rarer causes include other types of holes in the heart (like an atrial septal defect, or ASD), or a vascular communication in the lungs (like a pulmonary arteriovenous malformation, or AVM).
We are investigating whether people with a PE are at higher risk of stroke if they happen to have an RLS compared to PE patients who don't have an RLS. This study will simply observe and compare the differences in stroke-related outcomes between those 2 groups.
Participation in the study last roughly 90-days and includes the following activities:
You will be asked to return for a follow-up visit 90 days after your pulmonary embolism. At this visit, the following will occur:
Study participants will be selected from the population of patients admitted to Tufts Medical Center
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The RLS cohort includes: a) Subjects found to have a right-to-left shunt (RLS) using transcranial Doppler (TCD) with bubble study b) Subjects with a known RLS (i.e. previously investigated with TCD or TEE)
The No RLS cohort includes: a) Subjects with no RLS identified via TCD with bubble study b) Subjects known to not have an RLS (i.e. previously investigated with TCD or TEE)
Combined incidence of acute ischemic stroke and silent cerebral infarct
1. Acute ischemic stroke incidence through 90 days defined as an acute focal neurological deficit presumed to be due to focal cerebral or retinal ischemia and either: a) Persisting \>24 hours b) Persisting \<24 hours but associated with a neuroanatomically relevant cerebral or retinal infarct documented with MRI or CT or direct retinal observation. 2. Silent cerebral infarct through 90 days defined as the presence of at least one new hyperintense lesion of 3 mm or greater in diameter on T2-weighted MRI between the screening MRI and the 90-day MRI in the absence of a relevant clinical event.
Time frame: 90 Days
Ran from Jan 2026 to primary completion in Feb 2026, 0 months.
Of 135 non-industry observational studies under Pulmonary Embolism, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 119. This study's 0 months is below that.
Counting every sponsor, half of 160 studies reached it within 47 months; a quarter within 21 and three quarters within 105.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.